Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...

Pomalyst can cause certain adverse effects (side effects), some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. But if the side effects last ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Pomalyst is a top seller for Bristol Myers, bringing in nearly $3.5 billion out of $46.16 billion of its total revenue last year. The company in July forecast sales of the drug to fall this year, ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Also known as pomalidomide in generic terms, Pomalyst generated $2.7B in revenue for BMY in 2024 from the U.S. ahead of its anticipated patent cliff in Q1 2026. More on Cigna, Bristol-Myers Squibb ...

Pomalyst accounted for sales of more than $3 billion in each of the last five years, including $3.55 billion in 2024, accounting for 7% of Bristol's overall revenue of $48 billion. Related ...

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly ...

Pomalyst will be available in 1mg, 2mg, 3mg, and 4mg strength capsules in 21- and 100-count bottles. Pomalyst is expected to be available in about two weeks. Continue Reading.

Bristol Myers Squibb acquired Pomalyst when it purchased Celgene for $74 billion (₹6.15 lakh crore) in 2019. In 2022, Pomalyst generated nearly $3.5 billion (₹30,000 crore) in revenue, marking ...

Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial. News. Cancer Horizons All News Blogs ...